Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Pancholi S, Leal MF, Ribas R, Simigdala N, Schuster E, Chateau-Joubert S, Zabaglo L, Hills M, Dodson A, Gao Q, Johnston SR, Dowsett M, Cosulich SC, Maragoni E, Martin LA. Pancholi S, et al. Among authors: martin la. Breast Cancer Res. 2019 Dec 4;21(1):135. doi: 10.1186/s13058-019-1222-0. Breast Cancer Res. 2019. PMID: 31801615 Free PMC article.
Mechanisms of resistance to aromatase inhibitors.
Dowsett M, Martin LA, Smith I, Johnston S. Dowsett M, et al. Among authors: martin la. J Steroid Biochem Mol Biol. 2005 May;95(1-5):167-72. doi: 10.1016/j.jsbmb.2005.04.022. J Steroid Biochem Mol Biol. 2005. PMID: 15982868 Review.
311 results